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HER2, chromosome 17 polysomy 
and DNA ploidy status in breast 
cancer; a translational study
Altuna Halilovic  1,2, Dagmar I. Verweij1, Annet Simons3, Marian J. P. L. Stevens-Kroef3, 
Susan Vermeulen3, Janet Elsink3, Bastiaan B. J. Tops1, Irene Otte-Höller1, Jeroen A. W. M. van 
der Laak  1, Carlijn van de Water1, Oliver B. A. Boelens4, Margrethe S. Schlooz-Vries5, 
Jeroen R. Dijkstra1, Iris D. Nagtegaal1, Jolien tol6,7, Patricia H. J. van Cleef1, Paul N. Span8 & 
Peter Bult1
Breast cancer treatment depends on human epidermal growth factor receptor-2 (HER2) status, which 
is often determined using dual probe fluorescence in situ hybridisation (FISH). Hereby, also loss and 
gain of the centromere of chromosome 17 (CEP17) can be observed (HER2 is located on chromosome 
17). CEP17 gain can lead to difficulty in interpretation of HER2 status, since this might represent 
true polysomy. With this study we investigated whether isolated polysomy is present and how this 
effects HER2 status in six breast cancer cell lines and 97 breast cancer cases, using HER2 FISH and 
immunohistochemistry, DNA ploidy assessment and multiplex ligation dependent probe amplification. 
We observed no isolated polysomy of chromosome 17 in any cell line. However, FISH analysis did 
show CEP17 gain in five of six cell lines, which reflected gains of the whole chromosome in metaphase 
spreads and aneuploidy with gain of multiple chromosomes in all these cases. In patients’ samples, 
gain of CEP17 indeed correlated with aneuploidy of the tumour (91.1%; p < 0.001). Our results indicate 
that CEP17 gain is not due to isolated polysomy, but rather due to widespread aneuploidy with gain of 
multiple chromosomes. As aneuploidy is associated with poor clinical outcome, irrespective of tumour 
grade, this could improve future therapeutic decision making.
Human epidermal growth factor receptor-2 (HER2) status assessment is of pivotal importance for targeted ther-
apy for HER2 positive primary1–4 and metastatic5–7 breast cancer. The American Society of Clinical Oncology 
(ASCO) and College of American Pathologists (CAP) guideline for HER2 testing gives recommendations for 
testing by immunohistochemistry (IHC) and (fluorescence) in situ hybridization ((F)ISH). HER2 ISH may be 
evaluated with a single probe, but more often a dual probe is used8. Dual probe ISH includes a probe for the 
ERBB2(HER2) gene and a probe for the centromere of chromosome 17 (CEP17), so copy number changes can be 
found for both locations.
Loss of one chromosome 17 (leaving only one copy per nucleus) is called monosomy and chromosomal copy 
number gain (more than 2 copies per nucleus) is called polysomy9. Gain of CEP17, which is commonly inter-
preted as chromosome 17 polysomy, is said to be present in up to 68% of breast carcinomas according to var-
ious studies10,11. Recently, others have questioned the use of only the centromere region of chromosome 17 as 
a representative of the whole chromosome, arguing that the presence of true polysomy of chromosome 17 is a 
rare event12,13. Since chromosome 17 polysomy can give difficulties in interpretation of HER2 status assessment 
results13–15, it is vital to know if it is present.
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In addition to losses and gains of HER2 and CEP17, also copy number alterations of other parts of chro-
mosome 17 occur. Chromosome 17 includes many genes that are involved in breast carcinogenesis, including 
tumour-suppressor genes TP53, BRCA1 and TOP2A11. The clinical relevance of copy number alterations in these 
genes is not yet clear.
With the present study we aimed to investigate the presence or absence of chromosome 17 polysomy in rela-
tion to CEP17 gains and with respect to HER2 status assessment, by combining in vitro assays with clinical vali-
dation cases.
Results
Breast cancer cell lines. The analyzed six breast cancer cell lines showed variation in HER2 status (Table 1, 
Figs 1 and 2): two were amplified and four cell lines were not. There was perfect correlation of the HER2 status 
when comparing MLPA, IHC, FISH on cells and on metaphase spreads in all cell lines.
Gain of CEP17 was detected in five of six cell lines with FISH, in both the metaphase spreads and interphase 
cell nuclei. However, not one cell line showed isolated polysomy of chromosome 17 in the MLPA test (Fig. 2). 
Especially in metaphase spreads, copy number gain of the whole chromosome 17, and not only of the centromeric 
region could be appreciated (Fig. 1). Copy number gain of chromosome 17 correlated with a tetraploid or aneu-
ploid pattern with gains in the DNA ploidy assessment in five of six cell lines (three DNA histograms are shown 
in Fig. 3. These data show that copy number gain of CEP17 is not due to isolated chromosome 17 polysomy, but 
is a result of aneuploidy with gain of multiple chromosomes.
Cell line
HER2 IHC 
Agarcyto*
HER2 FISH 
Metaphase 
spreads (ratio)**
HER2 FISH 
Agarcyto (ratio)**
HER2 MLPA 
(ratio)***
CEP17 FISH number 
of signalsMetaphase 
spreads
CEP17 FISH 
number of 
signals Agarcyto
Copy number 
chromosome 17 
with MLPA
DNA ploidy 
status
MDA-MB231 0 1.19 0.88 1.23 4 4 2 Polyploid
MDA-MB436 0 1.00 1.00 0.71 1 1 1 Hypoploid
MCF7 1+ 0.69 0.85 0.63**** 3 3 2 Hyperploid
HCC1937 2+ 1.06 1.01 1.21 6 6 2 Hyperploid
OCUB-F 3+ ≫2 ≫2 7.78 4 4 2 Hyperploid
SK-BR-3 3+ ≫2 ≫2 6.11 6 5 2 Hyperploid
Table 1. Results of the breast cancer cell lines. *Scoring of 0, 1+, 2+ or 3+, **Ratio of spots for the HER2 
gene and CEP17; mean value of 2 independent estimations; ***Ratio as mean value of both MLPA kits used; 
****Partial loss of the HER2 gene.
Cancer cell lines
MDA-mb436 MCF7 OCUB-F SK-BR-3
Agarcyto IHC 
score
Metaphase 
spread FISH
Interphase 
spread FISH*
Agarcyto 
FISH*/**
Monosomy chromosome 17 Three chromosomes 17 Four chromosomes 17 Six chromosomes 17***
Figure 1. Examples of HER2 IHC of agarcyto slides and HER2/CEP17 FISH results on metaphase spreads, 
interphase nuclei, and agarcyto slides. Due to focusing (*) or cutting artefacts (**), not all of the spots of CEP17 
(green) or the HER2 gene (red) may be visible. ***HER2 gene amplified.
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Breast cancer cases. Next, we set out to assess whether our findings in the cell lines could be confirmed in 
97 breast cancer samples. The patient and tumour characteristics are summarized in Table 2. Based on the cen-
tromere probe for chromosome 17, 49 tumours (46.7%) showed copy number gain with 3 or more CEP17 signals 
(Table 2); 41(91.1%) of these showed aneuploid gains (including tetraploidy) and 4 (8.9%) showed diploidy. As 
such, finding more than 2 CEP17 signals strongly correlated with aneuploid gains (91.1%, p < 0.001). Pearson’s 
correlation between the number of CEP17 signals and DNA ploidy status is 0.579, with a sensitivity of 70.7%, a 
specificity of 89.7% and a positive and negative predictive value of 91.1% and 67.3%, respectively.
In accordance to our cancer cell line results, copy number gain of CEP17 is associated with DNA aneuploidy 
of the tumour with gain of multiple chromosomes. DNA ploidy assessment of the 97 breast tumours analyzed is 
shown in Table 3. DNA aneuploidy with gains was correlated with p53 mutant protein expression (p = 0,006), but 
not with DFS or DSS (p = 0.838 and 0.742, respectively) in our population.
Twenty two (22.7%) tumours showed HER2 gene amplification, 75 (77.3%) showed no amplification, of which 
nine (8.6%) showed a partial loss of the HER2 gene using FISH. In the HER2 negative group, 1 case (1.3%) was 
aneuploid with losses (Fig. 4a), 33 (44.0%) were diploid (Fig. 4b), and 41 (54.7%) aneuploid with gains (Fig. 4c). 
Of the tumours with a partial loss of the HER2 gene with the FISH test, 4 (44.4%) were diploid (Fig. 4b) and 5 
(55.6%) aneuploid with gains (Fig. 4d). Five (22.7%) of 22 HER2 positive cases were diploid (Fig. 4e) and 17 
(77.3%) showed an aneuploid DNA pattern with gains (Fig. 4f).
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Figure 2. MLPA results of chromosome 17 of all cell lines used. Cell lines MDA-MB231, HCC1937, MCF7, 
SK-BR-3, OCUB-F and MDA-MB436 are shown. Probemix P004-B1 and P078-B1 (greytone) were used on all 
cell lines. The HER2 gene is highlighted in red. The size of the used pictograms corresponds to the reach of the 
MLPA results (bigger size correlates to higher reach). Results between the probemixes were concordant. The 
P078-B1 breast tumour probemix also contained probes for genes located on other chromosomes relevant for 
breast carcinoma and reference genes. In these genes no polysomy or loss or amplification could be detected 
(not shown in the figure). Negative controls used, were nicely oriented around 1,00 (not shown). The MLPA 
results with probemix P004-B1 and P078-B1 (greytone) of cell lines MDA-MB231 and HCC1937 show no 
polysomy or loss or amplification of HER2. MCF7 shows partial loss of the HER2 gene, corresponding to FISH 
results (Table 1). SK-BR-3 shows amplification of the HER2 gene corresponding to IHC results and FISH results 
(Fig. 1). OCUB-F shows amplification of the HER2 gene corresponding to the IHC and FISH results (Table 1). 
MDA-MB436 shows partial loss of all tested genes on chromosome 17, concordant with monosomy, as was seen 
with FISH (Fig. 1).
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Discussion
CEP17 copy number gain can lead to difficulties in the interpretation of HER2 status, but it is still disputed 
whether this represents true chromosome 17 polysomy. Within the present study, we investigated the presence or 
absence of chromosome 17 polysomy in relation to CEP17 gains and HER2 status assessment.
Our in vitro experiments showed that CEP17 gains are actually gains of the whole chromosome and have a 
strong correlation with aneuploidy with gain of multiple chromosomes. Isolated chromosome 17 polysomy was 
not present in any of our cell lines. In our clinical study, over 90% of the patients with CEP17 copy number gain 
showed aneuploidy with gains. Our results of the cancer cell lines have furthermore shown excellent concord-
ance for HER2 status between IHC, FISH and MLPA, with comparable or better concordance than in previous 
studies13,16.
(F)ISH of CEP17 has generally been used as a surrogate for chromosome 17 copy number assessment in the 
absence of genetic analysis. Commonly, a mean CEP17 ≥ 3 is adopted as a threshold for polysomy of chromosome 
17. As such, the reported prevalence of chromosome 17 polysomy in various studies ranges from 3–68%10,11. 
More recently however, studies using array based techniques12,14,17, MLPA13 and extended FISH probe panels 
for chromosome 1716,18–20 all show that true polysomy, defined as copy number gain of (almost) all the genes on 
the chromosome, is a rare event, occurring in <1% of breast cancer cases. Indeed, in the present study we have 
shown that CEP17 gains in 5 of 6 breast cancer cell lines was not associated with true, isolated polysomy of chro-
mosome 17 in any of these cases. We did show aneuploidy with chromosomal copy number gain in all cell lines 
with CEP17 gain. So, there seems to be a gain of multiple chromosomes and not only chromosome 17 polysomy 
in tumours with CEP17 gains. Due to lack of ploidy assessment and metaphase spread assessment in previously 
conducted studies, this feature has not yet been revealed. Indeed, the methods used so far, MLPA, array-based 
comparative genomic hybridization (aCGH) and FISH for chromosome 17 with extended probe panels, are not 
optimally suited to detect polyploidy.
In the past, several studies have hinted at DNA aneuploidy in relation to CEP17 copy number gains, based on 
the association of copy number increases or “polysomy” of other chromosomes in association with chromosome 
17 “polysomy” using a variety of techniques18,21–23.
Aneuploidy, which is the presence of an abnormal number of chromosomes in a cell9, is the most common 
characteristic of human solid tumours and is said to contribute to, or even drive tumour development. It results 
from aberrant mitotic divisions, which can be caused by numerous factors. These include defects in duplication, 
maturation or segregation of centrosomes, defects in spindle attachment and chromosome cohesion, previous 
cytokinesis defects and impairment of the mitotic checkpoint response24. In invasive breast cancer, approximately 
80% of tumours show abnormalities in the structure and/or number of centrosomes, which shows a positive 
correlation with aneuploidy25. Centrosome defects are linked to chromosome missegregation during mitosis, but 
also to initiating micronucleus formation through merothelic chromosome attachments, chromosome breakage 
at centromeres, and DNA damage on miss attached chromosomes26. p53 status, a centrosome located protein, is 
also linked to aneuploidy and inactivation of this tumor suppressor can be an underlying genetic cause of cen-
trosome defects. Indeed, also in our population mutant p53 protein expression correlated with DNA aneuploidy 
(p = 0,006). On the other hand, others have demonstrated that centrosome abnormalities can lead to p53 inac-
tivation27,28. Also Nek2, which is a NIMA (never in mitosis A) related kinase, has a function as a major centro-
some regulator. This cell cycle-related protein kinase is overexpressed by all breast cancer subtypes compared to 
healthy tissue and was found to be important for tumor growth at primary and secondary sites. Nek2 knockdown 
induced aneuploidy and cell cycle arrest that led to cell death, especially in the triple negative subtype, indicating 
it as a interesting novel therapeutical target. This might sound counterintuitive, but aneuploidy and aberrant 
Human fibroblast control; euploid/diploid Cell line HCC1937; aneuploid/hyperploid, at FISH of the metaphase spreads 6 chromosomes 17 and HER2 negative 
Cell line MCF7; aneuploid/hyperploid, at FISH of the metaphase spreads 3 
chromosomes 17 and partly loss of the HER2 gene 
Cell line SK-BR-3; aneuploid/hyperploid, at FISH of the metaphase spreads 6 
chromosomes 17 and HER2 positive 
A B
C D
Figure 3. Cell line examples of DNA histograms of agarcyto material. IOD: integrated optical density.
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mitosis can also cause chromosomal breakage, resulting in a lethal genetic imbalance that leads to cell death29. 
Another interesting novel therapeutical target linked to centrosome function is KLF14 (Kruppel-like family of 
transcription factors 14). KLF14, which is often downregulated in human carcinomas, has a function in maintain-
ing the integrity of centrosomes by limiting Plk4 (Polo-like kinase 4) transcription, which is a master regulator 
of centriole duplication and assembly. Loss of KLF14 leads to centrosome amplification, genome instability and 
spontaneous tumour formation. On the other hand, enforced expression of KLF14 induces mitotic catastrophe, 
acting as a tumor suppressor30.
Established aneuploidy is a significant predictor for breast cancer progression and is correlated to worse clin-
ical outcome31. Not only is there a strong correlation between grade and ploidy status, but DNA ploidy can also 
subdivide patients with low grade breast carcinoma into different prognostic groups32. This finding can be of great 
clinical value, as it can help identify patients with low grade tumours who might benefit from adjuvant chemo-
therapy. CEP17 was shown to be a potential marker for aneuploidy, but also other centromere probes could be 
of interest. As dual probe FISH is already validated and often used in daily clinic practice for HER2 evaluation 
however, it will be feasible to also report the presence of copy number gains of CEP17 in pathology reports. 
This can trump subsequent ploidy assessment, which can be used for therapeutic decision-making in the future. 
Techniques like MammaPrint and Oncotype DX are already used by some as a tool to determine if adjuvant 
chemotherapy should be added to the treatment of patients with well and moderately differentiated tumours33. 
Patient and tumour characteristics HER2 + HER2 − Total (%)
Age at diagnosis [mean, year (range)] 55.6 (30–78) 57.9 (31–94) 57.2 (30–94)
Origin* (N (%)):
     Primary breast cancer 21 (20.8) 73 (72.2) 94 (96.9)
     Breast cancer metastasis 1 (33.3) 2 (66.7) 3 (3.1)
Tumour type* (N (%)):
     Invasive ductal carcinoma 21 (26.6) 58 (73.4) 79 (81.4)
     Invasive lobular carcinoma 1 (7.1) 13 (92.9) 14 (14.4)
     Apocrine carcinoma 0 (0) 1 (100) 1 (1.0)
     Micropapillary invasive carcinoma 0 (0) 1 (100) 1 (1.0)
     Mucinous carcinoma 0 (0) 1 (100) 1 (1.0)
     Tubular carcinoma 0 (0) 1 (100) 1 (1.0)
Tumour size (in cm)** (N (%)):
     0.5–2.0 9 (22.5) 31 (77.5) 40 (42.1)
     2.1–5.0 11 (23.4) 36 (76.6) 47 (48.5)
     >5.0 2 (25.0) 6 (75.0) 8 (8.3)
Tumour grade* (N (%)):
     I 0 (0) 12 (100) 12 (12.4)
     II 6 (16.7) 30 (83.3) 36 (37.1)
     III 16 (34.0) 31 (66.0) 47 (48.5)
     Not estimated 0 (0) 2 (100) 2 (2.1)
Oestrogen receptor* (N (%)):
     Positive 16 (19.8) 65 (80.2) 81 (83.5)
     Negative 6 (37.5) 10 (62.5) 16 (16.5)
Progesterone receptor*** (N (%)):
     Positive 8 (13.3) 52 (86.7) 60 (61.9)
     Negative 14 (38.9) 22 (61.1) 36 (37.1)
Lymph node status**** (N (%)):
     Not applicable 1(33.3) 2 (66.7) 3 (3.2)
     Positive 15 (35.7) 27 (64.3) 42 (44.2)
     Negative 5 (10.0) 45 (90.0) 50 (52.6)
HER2 status based on HER2/CEP17 FISH (N (%)):
     Positive 22 (22.7)
     Negative 75 (77.3)
     Partial loss of the HER2 gene 9 (12.0)
Number of chromosome 17 based on HER2/CEP17 FISH* (N (%)):
     1 2 (15.4) 11 (84.6) 13 (13.4)
     2 9 (23.1) 30 (76.9) 39 (40.2)
     ≥3 11 (24.4) 34 (75.6) 45 (46.4)
Table 2. Patient and tumour characteristics. *For total of 97 tumours. N: number of cases. **For total of 
95 tumours. For two samples the tumour size was unknown/not applicable. ***For total of 96 tumours. 
Progesterone receptor status was not determined on 1 tumour sample. ****For total of 95 patients.
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We propose the exploration for a similar role for the already widely used and relatively cheap dual probe FISH 
technique in larger cohorts. In our cohort, which was mixed with both primary and metastatic lesions and where 
patients received different treatments, we did not see a correlation between aneuploid gains and DFS or DSS. 
Our cohort however, was not selected for this purpose and is as such too heterogeneous, relatively small and has 
a short follow-up (median of 58 months). Pinto et al.32 for instance, who found that aneuploidy can identify sub-
sets of patients with poor clinical outcome in grade 1 and grade 2 tumours, included 684 patients with a median 
follow-up of 134.5 months. CEP17 copy number gain has furthermore also shown to be correlated to response 
to anthracycline based chemotherapy34,35. Considering above mentioned added value of combining a probe for 
CEP17 and a probe for the HER2/ERBB2 gene when performing HER2/ERBB2 gene ISH, we would like to advo-
cate the use of a double probe ISH in favour of a single probe ISH in all breast carcinomas.
Our results show that in a few of our breast tumours, CEP17 copy gain, based on the double probe FISH test, 
did not correlate with DNA aneuploid gains. There were 4 (8.9%) tumours with ≥ 3 CEP17 FISH signals and with 
Characteristics
DNA ploidy status
Aneuploid with 
loss N (%) Euploid N (%)
Aneuploid with 
gain* N (%)
HER2 status based on HER2/CEP17 FISH:
     Positive (N = 22) 0 (0) 5 (22.7) 17 (77.3)
     Negative (N = 75) 1 (1.3)** 33 (44.0) 41 (54.7)
       Partial loss of HER2 
(N = 9) 0 (0) 4 (44.4) 5 (55.6)
Number of chromosome 17 based on HER2/CEP17 FISH:
     1 1 (7.7) 9 (69.2) 3 (23.1)
     2 0 (0) 25 (64.1) 14 (35.9)
       ≥3 0 (0) 4 (8.9) 41 (91.1)
p53 protein expression
     Wildtype 1 (1,5) 32 (48,5) 33 (50,0)
     Mutant 0 (0) 6 (19,4) 25 (80,6)
       Overexpression 0 (0) 5 (21,7) 18 (78,3)
       Completely negative 0 (0) 1 (12,5) 7 (87,5)
Table 3. DNA ploidy assessment of 97 breast tumours analyzed. N: number of cases. *Including tetraploidy. 
**Probably aneuploid with loss, although morphologically it was not possible to differentiate tumour nuclei 
from normal nuclei.
Case 3; aneuploid/hypoploid, at FISH 1 chromosome 17 and HER2 negative* Case 100; euploid / diploid, at FISH 2 chromosomes 17 and partial loss of the HER2gene 
Case 36; aneuploid/hyperploid, at FISH 3 chromosomes 17, HER2 negative Case 88;  tetraploid / hyperploid, at FISH 4 chromosomes 17 and partial loss of the HER2 gene 
Case 58: euploid/diploid, at FISH 2 chromosomes 17 and HER2 positive Case 45; aneuploid / hyperploid, at FISH 6 chromosomes 17 and HER2 positive 
A B
C D
E F
Figure 4. Breast cancer examples of DNA histograms. IOD: integrated optical density. *Probably hypoploidy 
although morphologically it was not possible to differentiate tumour nuclei from normal nuclei.
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a diploid DNA status. Isolated centromere gains of chromosome 17 might explain why not all CEP17 gains are 
correlated with aneuploid gain12,13. Another explanation is variances in CEP17 signals due to genomic heteroge-
neity, proliferative activity and sectioning artefacts11. HER2 partial loss, as seen in nine of our cases (Table 3), can 
be due to rearrangement of chromosomes36.
It is of relevance to know if CEP17 gains are of importance for HER2 interpretation. The current ASCO/CAP 
guideline defines tumours as HER2 positive if the HER2/CEP17 ratio is ≥2.0 or if there are ≥6 HER2 genes per 
nucleus8. The addition of the latter was in order to minimize the effect of CEP17 variation on HER2 test results37. 
It is important to note that HER2 gains, both in absolute number and when considering the HER2/CEP17 ratio, 
are positively correlated with HER2 protein over-expression38. Furthermore, previous studies have shown that 
tumours with CEP17 gains in the absence of HER2 gene amplification resemble HER2 negative tumours, and do 
not seem to yield sensitivity for anti-HER2 directed agents15,39. Also, CEP17 gain seems not to be associated with 
clinical outcome in both the HER2 negative and the HER2 positive situation15,40.
Conclusions
This study has shown that copy number gain of CEP17, which is encountered regularly in HER2 testing of breast 
cancer, is due to gain of chromosome 17, which is a result of aneuploidy of the tumour with gain of multiple chro-
mosomes. As aneuploidy of breast carcinomas is associated with poor clinical outcome, also within low grade 
tumours, gain of CEP17 (and the associated correlation with aneuploid gain) might be used to select patients with 
a poor outcome and offer them adjuvant chemotherapy. Additional studies are however warranted to confirm our 
results and further test this hypothesis.
Methods
Cancer cell lines. Six breast cancer cell lines (MDA-MB231, OCUB-F, SK-BR-3, MCF7, MDA-MB436 and 
HCC1937) were used. All cancer cell lines were obtained from LGC Standards (Teddington, Middlesex, UK), 
with exception of the OCUB-F cell line, which was from Riken Gene Bank (Tsukuba, Japan). Identity of cell lines 
was authenticated by the suppliers by comparing growth properties and morphology. Species confirmation was 
performed by cytochrome oxidase I isoenzyme testing, and short tandem repeat analysis. Prior to this study, 
SK-BR-3 was known to be HER2 positive, HCC1937 was known to be HER2 negative, while no HER2 status was 
available for the other cell lines.
Cell culture. The breast cancer cell lines used were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 10% (vol/vol) fetal bovine 
serum (FBS, Sigma-Aldrich corporation, St. Louis, MO, USA), 20 mM Hepes, 1× nonessential amino acid, 2 
mM L-glutamine and 10 U/ml penicillin, 10 μg/ml streptomycin (all from PAA Laboratories, Cölbe, Germany) at 
37 °C with 5% CO2 as described before41. Hanks’ Balanced Salt Solution (HBSS, PAA Laboratories) was used as a 
washing. Cells were incubated under standard conditions before processing. Metaphase and interphase spreads 
for subsequent FISH analysis were prepared according to standard procedures42.
Agarcyto cell block preparation. We modified the agarcyto cell block preparation, which was described 
previously43; the first centrifugation was performed for 10 min at 217 × g and the second for 10 min at 867 RCF. 
The pellet was resuspended in 1 ml 2.25% liquid agarose (Agar technical, Agar No 3, Oxoid BV, Badhoevendorp, 
the Netherlands) at 60 °C. The third centrifugation was 10 min at 867 RCF to concentrate the cells in the agar. The 
agar cell pellet was then solidified at 4 °C for 30 min. The tissue was embedded in paraffin using an automated 
tissue processor (Pathos; Milestone, Sorisole (BG), Italy) under standard conditions for surgical biopsies. From 
the agarcyto block, 4 µm sections were cut and stained with hematoxylin-eosin (H&E) for cytomorphological 
examination.
P53 and HER2 IHC and HER2 FISH. P5344 and HER2 IHC45 and HER2 FISH46 were performed and 
scored as described elsewhere. For the ISH process, custom made probe ERBB2-HER2/Neu 17Q12/SE-17 (KB-
00007 Kreatech, Leica, Rijswijk, The Netherlands) was used. Scoring of HER2 IHC and FISH was conducted as 
described by the latest ASCO/CAP guideline for HER2 status assessment8.
Multiplex ligation-dependent probe amplification (MLPA). DNA was isolated with the QIAamp 
DNA micro kit (category no. 56304, Qiagen, Venlo, The Netherlands) according to the manufacturer’s instruc-
tions, with a few alterations. Step 12 included adding of 30 µl elution AE buffer (Qiagen) on the column and 
incubation for 1 min at room temperature before centrifugation for 1 min at 6000 × g. This was repeated once 
more, before the isolated DNA was judged for concentration and purity using the Nanodrop Spectrophotometer 
(NanoDrop Rechnologies Inc., Wilmington, DE, USA).
Next the DNA solution was used in the MLPA analysis according to the manufacturer’s instructions, using 
the P004-B1 ERBB2 probemix and the P078-B1 breast tumour probemix (both MRC Holland, Amsterdam, The 
Netherlands; access to precise contents via www.mlpa.com). PCR products were analyzed in a 3730XL DNA 
Analyzer. Gene copy numbers were analyzed using Genemapper v4.0 software. This software analyzed peak 
heights of all the genes present in the MLPA kits. These numbers were implemented in an excel template and val-
ues were automatically calculated and formed into a copy number graph. A value between 0.7 and 1.3 was defined 
as normal. A value below 0.7 was defined as a gene lost, a value between 1.3 and 2.0 as low level amplification and 
values > 2.0 as high level amplification according to the definitions in the software.
Breast cancer cases. From December 2010 until March 2013 a total of 698 breast carcinomas were tested 
for HER2 with a double probe FISH test at the department of pathology of the Radboud university medical 
center (Radboudumc) in Nijmegen, The Netherlands. From this series, a total of 97 tumours were selected for 
8Scientific RepoRtS |         (2019) 9:11679  | https://doi.org/10.1038/s41598-019-48212-2
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this study, based on the availability of a resection specimen for DNA ploidy assessment, which was dependent on 
the size of the tumour and quality of DNA. Patients were either treated in hospital Pantein in Boxmeer or in the 
Radboudumc in Nijmegen. No ethical approval was required according to current Dutch legislation, as we used 
leftover coded material47 and patients were given the opportunity to object to their leftover material to be used in 
(clinical) research. Following the observation of aneuploidy, survival data were also obtained for all cases. Disease 
free survival (DFS) was determined from the date of the initial diagnostic biopsy until affirmed recurrence of 
disease and disease specific survival (DSS) from the date of the initial diagnostic biopsy until death due to breast 
cancer.
DNA ploidy measurement of isolated nuclei from thick sections. Feulgen-Schiff stained cytospins 
containing nuclei isolated from 50 μm thick sections were prepared as described before48, and in accordance with 
the consensus criteria of the European Society for Analytical Cellular Pathology (ESACP)49. Briefly, nuclei were 
isolated using digestion with 2 ml 0.5% (w/v), pepsin pH1.5 (Sigma Aldrich, St. Louis, MO) for 60 min at 37 °C. 
Five min digestion was used for sections from agarcyto embedded tumour cell cultures. Hydrolysis was per-
formed using 5 N HCL at 25 °C for 60 min. Next, specimens were stained with Schiff ’s reagent (Merck, Darmstadt, 
Germany) at RT for 60 min.
DNA ploidy status was assessed according to the ESACP criteria49, using a QPath image cytometry station 
(Leica Microsystems GmbH, Wetzlar, Germany). The system acquires digital images using a monochromatic 
CCD camera attached to a Leica DM LB2 microscope using a 40x objective (Leica HCX PL Fluotar, N.A. = 0.75; 
resulting specimen level pixel size 0.326 × 0.326 μm2). Cytospins were measured fully automatically. The system 
allows definition of criteria that objects have to meet before being included in the final data set. Criteria applied 
in this study were: area between 50 and 850 pixels and roundness (defined as perimeter2/(4 * PI * area)) smaller 
than 1.25. Based on previous experience, these criteria minimize the amount of debris entering the analysis with-
out rejecting true nuclear objects. DI histograms were manually classified by three independent observers (JvdL, 
IO-H, DV). In case of interobserver discrepancy, consensus was reached by jointly evaluating cases. Histograms 
were classified as: tetraploid histogram: >15% of cells in the tetraploid region and 5c exceeding rate >1%; aneu-
ploid histogram: presence of a peak outside the diploid and tetraploid regions, or 2.5% of cells with DNA index 
exceeding 5c; or diploid histogram: all others.
Statistical analysis. Data was analyzed using IBM SPSS Statistics for Windows (version 20.0, IBM Corp., 
Armonk, NY, USA). The statistical correlation between the number of CEP17 signals and ploidy status were 
assessed using Pearson’s rho and the correlation between p53 status and ploidy status using Pearson’s Chi-Square 
test of independence. P values less than 0.05 were considered significant. Sensitivity, specificity, positive- and 
negative predictive values were calculated in order to determine the accuracy of the amount of CEP17 signals in 
predicting DNA ploidy status assessment. DFS and DSS curves were estimated by the Kaplan-Meier method and 
compared by means of the log-rank test for all primary tumours.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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